Background: Tylosin is commonly prescribed to dogs with diarrhea. Orally administered antibiotics may alter the intestinal microbiota, which is responsible for crucial key bile acid (BA) biotransformation reactions.
| INTRODUCTION
Tylosin is a macrolide antibiotic commonly prescribed as symptomatic treatment for acute or chronic diarrhea in dogs. 1, 2 Why fecal consistency improves is unknown but is thought to involve modulation of the intestinal microbiota. In the past, it was proposed that dogs with socalled tylosin-responsive diarrhea shared a common enteropathogen.
However, this hypothesis has not been substantiated. 3, 4 Other hypotheses about tylosin's mode of action include promotion of beneficial commensal bacteria, decrease in total bacterial load in the small intestine, and suppression of aberrant mucosal immune responses. 5, 6 Various studies have attempted to characterize tylosin's impact on the intestinal microbiota. In 5 healthy, fistulated, research Beagle dogs treated with tylosin PO q24h for 14 days, 16S rRNA sequencing of jejunal brush samples showed significant increases of Enterococcuslike organisms during treatment. 7 Concurrently, all samples exhibited decreased bacterial diversity. Certain taxa remained significantly altered 14 days after stopping tylosin. Another study found that Enterococcus spp. and lactic acid bacteria became more prevalent in fecal samples from 11 client-owned dogs with diarrhea that resolved during 7 days of PO tylosin. 8 Studies evaluating the impact of tylosin on the fecal microbiota of client-owned, healthy dogs utilizing culture-independent techniques are lacking.
Orally administered antibiotics are known to markedly disrupt the fecal microbiota and metabolome. [9] [10] [11] Bile acids (BAs) are a class of metabolites that link host health and microbiota composition. Bile acids within the intestinal lumen regulate the microbiota both directly and indirectly. 12 Selected bacterial species such as Clostridium hiranonis, C scindens, and C sordellii perform 7α-dehydroxylation required to convert primary to secondary BAs. 12, 13 Because of bacterial biotransformation, secondary BAs predominate in the feces of healthy individuals. 14 Thus, changes in the microbiota can result in altered fecal BA profiles. 15 It is unknown if tylosin treatment impacts BA homeostasis.
The purpose of our study was to analyze bacterial communities and selected unconjugated BAs (UBAs) in a time series of fecal samples obtained from healthy dogs before, during, and after 7 days of tylosin PO q12h. A 7-day duration was chosen because previous evidence suggested that PO antibiotics impact the fecal microbiota within 2 to 3 days. 9 We also wanted to maximize compliance and minimize adverse outcomes. In humans, longer courses of antibiotics result in greater selection pressure for resistant strains and increased risk of enteropathogenic infection with Clostridium difficile. 16 Fecal samples of dogs given placebo PO q12h for 7 days were evaluated longitudinally for comparison.
| MATERIALS AND METHODS

| Animals
The study was approved by the Institutional Animal Care and Use Committee at Colorado State University (protocol number . 
| Study period
A randomized, double-masked, placebo-controlled prospective observational study was performed ( Figure 1 ). No changes in diet or medication (including probiotics) were permitted during the 2-month study period. Dogs already on medications chronically were allowed to continue those medications provided there had been no changes in the month before enrollment (day 0). Subsequently, the owner was asked to collect fecal samples on days 21 (2 weeks after stopping the drug) and 63 (2 months after stopping the drug) and bring them to the clinic as previously described. Samples were refrigerated for up to 7 days before being frozen for storage at −80 C. Samples were batch-shipped on dry ice to the Texas A&M Gastrointestinal Laboratory for analysis.
| DNA extraction
All samples underwent 1 freeze-thaw cycle before DNA extraction.
Fecal DNA was extracted from a 100 mg aliquot of feces using the DNeasy PowerSoil Kit (QIAGEN Inc, Germantown, Maryland) according to the manufacturer's instructions.
| Quantitative PCR
To quantify the abundance of selected bacterial groups (Universal, Blautia spp., C hiranonis, E coli, Faecalibacterium spp., Fusobacterium spp., Streptococcus spp., Turicibacter spp.), quantitative PCR (qPCR) was performed as previously described 17 on all fecal samples collected (n = 81). Results were expressed as the log amount of DNA (fg) for each particular bacterial group per 10 ng of total isolated DNA. A mathematical algorithm was employed to convert these abundances into a single descriptive numeric value, the dysbiosis index (DI). 17 Clostridium perfringens DNA also was quantified using qPCR as previously described. 18 Quantitative PCR analysis of the samples was completed on 6 separate instances over the course of 12 months.
| 16S rRNA sequencing
A subset of samples, including all provided from days 0, 7, and 63, was submitted for sequencing of the 16S rRNA gene. Amplification and sequencing of the V4 variable region was performed en masse as previously described 18 with a few alterations. Raw sequence data were processed and analyzed using QIIME pipeline version 1.9.1. 19 Sequences were filtered for chimeras using USEARCH61 20 
| Statistical analysis
Descriptive statistics were calculated for each variable. Data were assessed for normality using the Shapiro-Wilk test and expressed as mean and standard deviation or median and range (minimum-maximum).
Within each treatment group, fecal scores during the 7-day period of administration were compared to the day 0 fecal score using The number of dogs with ≤10% and >10% primary fecal UBA was compared between treatment groups at days 0, 7, 21, and 63 using
Fisher's exact test. Total, primary and secondary UBA concentrations were compared over time using a mixed effects model with an AR(1) covariance structure, using the aforementioned fixed effects and Tukey-Kramer post hoc analysis.
Significance was set at P < .05. Statistical analyses were performed using commercially available software (Prism 8 for macOS ver- 3 | RESULTS
| Animal population
A total of 18 dogs initially were enrolled. Dog 2 initially tested positive for hookworms; it was treated with fenbendazole (50 mg/kg PO q24h for 5 days) and enrolled 8 months after initial screening when a subsequent fecal screen was negative. Two dogs (12 and 13) had to be excluded because the owners only provided samples from 1 and 2 time points, respectively.
Baseline characteristics of the 16 dogs completing the study are presented in Table 1 with additional details provided in Table S1 .
Seven dogs (2 in the placebo group, 5 in the tylosin group) had previous medical diagnoses that were not expected to interfere with the study. Three of the 16 dogs were on long-term daily medications: 
| Study period
Owners did not express concerns regarding adverse effects nor did they report occurrence of diarrhea in their dogs during study drug administration. All owners provided completed fecal scoring sheets when submitting the day 7 sample. Empty pill vials were not collected.
In both the placebo and tylosin groups, day 0 fecal scores were not Table 2 significantly different from any time point during the 7-day treatment period ( Figure 2 ). The median day 7 fecal score in both groups was 2.
Owners Table S2 ). Treatment and time independently influenced Blautia (F ratio, 5.63; P = .03, and F ratio, 3.95; P = .04, respectively), but the effect of their interaction did not reach significance. Adjustment for multiple comparisons indicated significant differences in log bacterial abundance between days 0 and 7 samples of the tylosin-exposed dogs. Blautia (P = .03), C hiranonis (P = .01), Faecalibacterium (P < .001), Fusobacterium (P < .001), and Turicibacter (P = .002) were significantly decreased at day 7 compared to day 0, as shown in 
| Beta diversity
The ANOSIM of unweighted and weighted UniFrac distances within the placebo group (Table 2) , displayed in PCoA plots (Figure 4 ), showed no significant differences in β-diversity among fecal bacterial communities in dogs given placebo over time. Conversely, significant differences in β-diversity were identified between days 0 and 7 fecal bacterial communities in dogs given tylosin. At day 63, communities were significantly different based on unweighted analysis but not on weighted analysis.
| Alpha diversity
The interaction between treatment and time influenced alpha diversity ( Table 3 ). The post hoc analysis indicated significant decreases in By day 63, alpha diversity was not significantly different compared to day 0. In the placebo group, no significant differences were identified in alpha diversity measures over time. 
| Linear discriminant analysis effect size
| Univariate analysis
Summary statistics of the main bacterial taxa identified in the 16S rRNA gene analysis are presented in Table S3 . In both groups at day 0, >90% of sequences belonged to the Firmicutes, Fusobacteria, and Veillonellaceae abundances changed differently between the 2 groups.
After adjustment for multiple comparisons, the only taxa that changed differently were Paraprevotellaceae (q = .020) and Peptostreptococcaceae (q = .049). Paraprevotellaceae were decreased more frequently, and
Peptostreptococcaceae were increased more frequently or not changed at day 7 compared to day 0 in dogs given tylosin. Comparing relative abundance shifts between day 0 and day 63 samples, no taxa changed differently between the placebo-and tylosin-exposed dogs.
| Fecal unconjugated BAs
The UBA profiles were composed of >90% secondary UBAs (DCA and LCA) in day 0 fecal samples from 5 of the 8 dogs in the placebo group and 7 of the 8 dogs in the tylosin group ( Primary UBA concentrations ( Figure 6) were influenced by the interaction between treatment and time (F ratio, 4.20; P = .001; Table 5 ). Concentrations of primary UBAs were significantly higher at day 21 (P = .04, Figure 6 Alternatively, no obvious adverse gastrointestinal signs were observed in other groups of dogs given PO metronidazole, tylosin, or amoxicillin. 7, 28, 29 Thus, the development of antibiotic-associated adverse gastrointestinal signs in dogs appears to be both drug-and host-specific.
The lack of change in fecal consistency during tylosin administration was contrasted by marked changes observed in fecal microbiota during and after administration of this drug. During tylosin administration, the fecal microbiota showed significant decreases in diversity and alterations in community structure. Dogs given placebo had stable diversity and community structure over the study period, and so we attribute the aforementioned alterations to the antibiotic. These observations were not surprising. Microbiota disruption has been documented in healthy dogs and humans receiving PO antibiotics. 7, 11, [28] [29] [30] Alteration of gut microbiota is not necessarily detrimental to the host, and different microbiota compositions can be compatible with health. 31 However, a healthy microbiota tends to be very diverse. 32, 33 The connection between antibiotic administration and disruption of the normal microbiota and self-limiting diarrhea is well-established in humans. [34] [35] [36] Long-term consequences, although more challenging to predict, also occur. Of note, antibiotic exposure early in life has been associated with increased risk of food allergy and Crohn's disease in humans. 37, 38 Epidemiological studies are needed to determine if these types of unintended health effects occur in dogs exposed to tylosin or other antibiotics, particularly in light of their widespread use. 1, 39 Tylosin is a macrolide antibiotic, and Gram-positive bacteria were expected to decrease during exposure. 40 In the healthy dogs randomized to receive tylosin, 16S rRNA gene sequencing demonstrated decreases in Fusobacteriaceae, Ruminococcaceae, and Veillonellaceae. Parallel qPCR results showed significant decreases in Fusobacterium and Faecalibacterium, supporting these findings. Decreases in Blautia and C hiranonis also were apparent in both analyses. All the families indicated to be most susceptible to tylosin were anaerobes. Interestingly, many of these same taxa were decreased in fecal samples from healthy dogs
given PO metronidazole. 28 The ramifications of widespread decreases in anaerobes are unclear. Although certain commensal Fusobacterium spp.
have been found to act as pathogens in susceptible human hosts, inciting colonic inflammation, 41 in dogs, Fusobacterium consistently has been associated with health. 42, 43 Faecalibacterium also has been associated with health and are thought to benefit the host by short-chain fatty acid production. 44 Overall, we are cautious to avoid overinterpreting changes in any single bacterial taxon. Further work is needed to investigate the implications of decreases in these anaerobes.
In these healthy dogs, Enterococcaceae and Peptostreptococcaceae increased in relative abundance during tylosin administration. Increases in fecal Enterococcus spp. during PO tylosin have been reported previously in both healthy and diarrheic dogs. 7, 8 This is notable given the disparate patient populations (client-owned versus research Beagle), dosing (once versus twice daily), duration (14 versus 7 days), samples analyzed (fecal versus jejunal brush), and methodologies (cultivationbased versus molecular) utilized among studies. Likely, these families increased proportionally during tylosin administration because of intrinsic or acquired antimicrobial resistance. Increases in both families appeared to be transient (Table S3 ), suggesting that once selection pressure is removed, resistant groups lose their selective advantage.
In contrast to the generally uniform changes in the fecal microbiota during tylosin administration, changes after cessation were not uniform ( Figure S1 ). Some dogs (e.g., dogs 3 and 4) generally recovered to a pretreatment state 2 months after tylosin cessation ( Figure 5 ). On the other hand, fecal microbial communities at the family level in dogs returned to a normal DI by day 63. Our observations mimic the unpredictable post-antibiotic period documented in the jejunal microbiota of healthy Beagles after 14 days of tylosin, 7 as well in healthy humans after antibiotic exposure. 10, 11, 45 Based on the individualized changes observed in the dogs of our study, we were not able to draw any broad conclusions regarding tylosin's expected duration of impact across a population. We therefore conclude that 2 months after PO tylosin exposure, reestablishment of the native microbiota is possible but not guaranteed. These observations are relevant for interpretation of past and future microbiome studies in dogs, which almost always involve subjects with historical antibiotic exposure.
Tylosin has been suggested as a treatment for diarrhea attributed to Clostridium perfringens. 46, 47 However, tylosin administration was not associated with a consistent decrease in the prevalence of fecal C perfringens. This was reported previously in the jejunal microbiota of healthy Beagles, 7 and might be attributed to a disrupted intestinal microenvironment where commensal enterotoxigenic C perfringens are encouraged to sporulate. 48 It is also plausible that macrolideresistant C perfringens were present. 46 Further investigations into the relationships between tylosin and enteropathogenic bacteria, particularly in dogs with diarrhea, are warranted.
Tylosin administration was associated with increases in primary UBA concentrations ( Figure 6 ) and proportions in the feces ( 49 permeability, 50 and secretory activity, 51 as well as to induce apoptosis in colonic epithelial cells. 52 In people with irritable bowel syndrome (IBS), >10% primary fecal BAs were 91% and 87% specific for increased fecal weight and increased colonic motility, respectively. 53 The absence of diarrhea in our tylosin-exposed dogs, all of which had >10% primary UBAs at day 7, suggests that this factor in isolation is not sufficient to cause diarrhea. A probable explanation for this finding is that the microbiota and metabolome, as well as the host immune response, must be altered to a certain extent (not achieved in our dogs) before clinical signs ensue. The fecal UBA dysmetabolism documented in these healthy dogs with tylosin administration is a novel finding, and future, longitudinal, hypothesis-driven studies are needed to evaluate its prevalence and associated consequences.
Our study had a number of limitations. First, we tested many dependent variables in each sample, thus increasing the chance of false discovery, particularly for the 16S rRNA gene results. For this reason, we were conservative in our interpretation of the univariate data. This cautious approach, combined with the small sample size used, would have increased the type II error. Compounding our small sample size, samples from certain time points were not available. Therefore, our study lacks power to make definitive conclusions regarding the time needed for recovery of fecal microbiota and UBA profile. Lastly, as with any 16S gene sequencing microbiota analysis, it is important to bear in mind that results are compositional in nature, and an increase in proportion does not necessarily translate into an increase in absolute abundance of bacteria. 54 Hopefully, these preliminary findings will lead to future hypothesis-driven research into the long-term effects of tylosin administration in dogs, especially those with chronic enteropathy.
This cohort included dogs receiving medications chronically. Because these were given consistently before and during the study period, it is unlikely that differences observed between treatments and time points were considerably confounded by these medications. We excluded dogs with PO antibiotic exposure in the preceding 4 months, but other exposures could be relevant. In humans, repeated antibiotic courses may result in a microbiota that is less able to recover from future perturbations. 10 Finally, the cohort included some dogs with historical gastrointestinal signs.
It is possible that some had occult gastrointestinal disease during the study period. Ultimately, our study provides useful information because (i) all dogs met criteria of clinical health at enrollment, (ii) the baseline microbiota across groups was comparable to previous descriptions of healthy fecal microbiota in dogs, 43 and (iii) attributes such as chronic medications and previous illnesses would be expected to make the group more rather than less representative of dogs that would actually be prescribed tylosin.
Although fecal sample handling was not entirely uniform, we do not believe this confounded microbiota results. Fecal microbiota populations based on 16S rRNA gene sequencing are stable during storage at room temperature for 24 hours. 55 Data from our laboratory suggest that the fecal microbiota is stable at 4 C for at least 7 days (JSS, unpublished data). Samples were stored at 4 C to avoid freezethaw cycles that could impact fecal metabolite yield, 56 because fecal UBAs may be more sensitive to storage conditions than bacterial DNA.
Bile acid analysis was limited to a subset of unconjugated BAs.
Increases in conjugated and sulfated fecal BAs have been documented in humans with IBS 15,57 and could have implications for host health.
Lastly, 1 aliquot from 1 bowel movement may not be representative of the luminal BA milieu given variation in BA excretion. 56 
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